General Description

Sage Therapeutics

Youtube Subscribe

Ticker: SAGE

Sector: Biotechnology

25 out of the 910 hedge funds surveyed by Insider Monkey had bought and owned Sage Therapeutics, Inc. The company has a 52 week low of $22.51 and a high of $59.99. Tower Research Capital.

Extended Summary

Sage Therapeutics

Recent study raises questions about safety of Sage Therapeutics Zurzuvae (zuranolone) for postpartum depression, charging that the drug exerts risks similar to those seen with benzodiazepines. 25 out of the 910 hedge funds surveyed by Insider Monkey had bought and owned Sage Therapeutics, Inc. (NASDAQ: SAGE) As of September 2023, 25 of the 10,000 hedge fund investors surveyed had bought the company. The company has a 52 week low of $22.51 and a high of $59.99. Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Tower Research Capital LLC TRC increased its holdings in Sage Theraputics by 74.0% during the third quarter. Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. The firm encourages investors to contact the firm. The firm is investigating potential claims against Sage Theraputics. Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. Company size 501-1,000 employees is expected to be around 690.

Related Results

February 16, 2024 7:41 (London Time)